ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · HP_0000989

Pruritus

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. Pruritus. Diseases, record HP_0000989. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000989

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
Pruritus
Open Targets ID
HP_0000989
Other names
Itching, Itchy skin, Skin itching
Highest stage of its drugs
Approval, for 63 of its 125 drugs, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD

Source Open Targets

Drugs125

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
DIFELIKEFALINCHEMBL3989915ProteinApprovalClinicalTrials.gov, EMA Human Drugs and TTD191717Drugs and targets
NALFURAFINE HYDROCHLORIDECHEMBL490665Small moleculeApprovalPMDA544Drugs and targets
NEMOLIZUMABCHEMBL4297794AntibodyApprovalPMDA544Drugs and targets
LIDOCAINECHEMBL79Small moleculeApprovalATC and DailyMed2022Drugs and targets
DESLORATADINECHEMBL1172Small moleculeApprovalDailyMed and PMDA422Drugs and targets
ODEVIXIBATCHEMBL4297588Small moleculeApprovalEMA Human Drugs and TTD422Drugs and targets
DIPHENHYDRAMINECHEMBL657Small moleculeApprovalATC322Drugs and targets
DIMETHINDENECHEMBL22108Small moleculeApprovalATC211Drugs and targets
DOXEPINCHEMBL1628227Small moleculeApprovalATC211Drugs and targets
LEVOCETIRIZINE DIHYDROCHLORIDECHEMBL1201190Small moleculeApprovalPMDA211Drugs and targets

1 to 10 of 125

See all 125 drugs

Targets80

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
HRH1Histamine H1 receptor25Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonistApprovalhttps://conductscience.org/library/genes/3269Drugs and targets
OPRM1Mu-type opioid receptor10Mu opioid receptor agonist; Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonistPhase 3https://conductscience.org/library/genes/4988Drugs and targets
OPRK1Kappa-type opioid receptor9Kappa opioid receptor agonist; Kappa opioid receptor partial agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonistApprovalhttps://conductscience.org/library/genes/4986Drugs and targets
SLC10A2Ileal sodium/bile acid cotransporter6Ileal bile acid transporter inhibitorApprovalhttps://conductscience.org/library/genes/6555Drugs and targets
OPRD1Delta-type opioid receptor5Delta opioid receptor antagonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonistPhase 3https://conductscience.org/library/genes/4985Drugs and targets
SCN10ASodium channel alpha subunit4Sodium channel alpha subunit blocker; Sodium channel protein type X alpha subunit blockerApprovalhttps://conductscience.org/library/genes/6336Drugs and targets
SCN5ASodium channel alpha subunit4Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blockerApprovalhttps://conductscience.org/library/genes/6331Drugs and targets
TACR1Substance-P receptor4Neurokinin 1 receptor antagonistPhase 3https://conductscience.org/library/genes/6869Drugs and targets
NR3C1Glucocorticoid receptor3Glucocorticoid receptor agonistApprovalhttps://conductscience.org/library/genes/2908Drugs and targets
PPARDPeroxisome proliferator-activated receptor3Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor delta agonistPhase 3https://conductscience.org/library/genes/5467Drugs and targets

1 to 10 of 80

See all 80 targets

Trials110

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT03540160Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)Phase 35582020-11-30Pruritus, Prurigo Nodularis, Atopic Dermatitis, PsoriasisSERLOPITANTIts record names the diseaseClinicalTrials.gov
NCT02975206Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic DermatitisPhase 24842019-03-05Pruritus, Atopic DermatitisSERLOPITANTIts record names the diseaseClinicalTrials.gov
NCT03636269CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusPhase 34732022-04-26Uremic PruritusDIFELIKEFALINIts record names the diseaseClinicalTrials.gov
NCT03422653A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)Phase 33782022-04-26Uremic PruritusDIFELIKEFALINIts record names the diseaseClinicalTrials.gov
NCT03677401Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisPhase 32952020-10-28Pruritus, Prurigo NodularisSERLOPITANTIts record names the diseaseClinicalTrials.gov
NCT03281538Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe PruritusPhase 32882021-10-14Uremic PruritusDIFELIKEFALINIts record names the diseaseClinicalTrials.gov
NCT03546816Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisPhase 32852020-09-07Pruritus, Prurigo NodularisSERLOPITANTIts record names the diseaseClinicalTrials.gov
NCT03617536A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe PruritusPhase 22692024-01-24Chronic Kidney Diseases, PruritusDIFELIKEFALINIts record names the diseaseClinicalTrials.gov
NCT02935699Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute UrticariaPhase 32622019-11-27Acute UrticariaCETIRIZINE, DIPHENHYDRAMINEIts record names the diseaseClinicalTrials.gov
NCT05885737Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe PruritusPhase 32602025-09-12Uremic PruritusDIFELIKEFALINIts record names the diseaseClinicalTrials.gov

1 to 10 of 110

See all 110 trials

Comparisons in its trials41

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Serlopitant 5 mg vs Placebo: deaths from any cause1 of 1470 of 148295NCT03677401Trial comparisons
Serlopitant 5 mg vs Placebo: serious adverse events5 of 1472 of 148295NCT03677401Trial comparisons
Serlopitant 5 mg vs Placebo: deaths from any cause0 of 1390 of 141280NCT03546816Trial comparisons
Serlopitant 5 mg vs Placebo: serious adverse events6 of 1393 of 141280NCT03546816Trial comparisons
Test Drug vs Control: Number of Patients Who Needed to Return to Treatment Center7 of 12719 of 135262NCT02935699Trial comparisons
Test Drug vs Control: deaths from any cause0 of 1270 of 135262NCT02935699Trial comparisons
Test Drug vs Control: serious adverse events0 of 1271 of 135262NCT02935699Trial comparisons
Difelikefalin/Difelikefalin vs Placebo/Difelikefalin: Number of Participants With Clinically Relevant Change From Baseline in Vital Signs and Laboratory Evaluations0 of 1290 of 130259NCT05885737Trial comparisons
Serlopitant 5 mg vs Placebo: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 1044 of 11646 of 117233NCT03841331Trial comparisons
Serlopitant 5 mg vs Placebo: deaths from any cause0 of 1160 of 117233NCT03841331Trial comparisons

1 to 10 of 41

See all 41 comparisons in its trials

Papers from its trials92

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
41105816RESULT1PubMed
32328775RESULT1PubMed
31541747RESULT2PubMed
27521593RESULT1PubMed
25971957RESULT2PubMed
24517320RESULT1PubMed
24106351RESULT1PubMed
22995650RESULT1PubMed
22870909RESULT1PubMed
22850916RESULT1PubMed

1 to 10 of 92

See all 92 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000989

GET https://conductscience.org/api/diseases/v1/HP_0000989/drugs?page=2

API referenceFor AI assistants